aging
Does mild kidney impairment ruin AD blood tests?
Open access · cc by · source: Europe PMC
In 242 TRIAD participants, eGFR related to some plasma AD biomarkers, but adding eGFR did not improve Aβ-positivity prediction beyond age/sex and the biomarker itself.
Key findings
Levels were highest in CKD stage 3 for some markers (significant for NfL, Aβ42, Aβ40). Many eGFR associations shrank after age/sex/Aβ-PET adjustment; adding eGFR did not improve AIC or AUC for Aβ-positivity. Authors conclude normal-to-mild renal impairment is not clinically decisive for accurate markers like p-tau217.
Methodology
Measured eGFR from plasma creatinine and multiple Simoa plasma biomarkers (Aβ42/40, GFAP, NfL, p-tau isoforms, NTA-tau) in 242 TRIAD participants, then tested associations and Aβ-positivity models with/without eGFR.
Limitations
Few participants had advanced CKD, so results do not rule out clinically important confounding in severe kidney disease.
How this study connects
Role on claims
Each row is a claim on a concept or method page where this paper supports, challenges, or qualifies the statement. Roles are hand-checked — not a model guess.
Not yet placed on a claim. This paper has study layers, but no concept page yet cites it as support, challenge, or qualifier.
Related papers in this topic
Same topic cluster — not a recommendation engine.